E. Morozova, T. Rudakova, J. Vlasova, M. Barabanshchikova, Tatiana Gindina, A. Alyanskiy, M. Vladovskaya, I. Moiseev, L. Zubarovskaya, A. Kulagin
{"title":"同种异体造血干细胞移植治疗慢性髓性白血病后与原发性移植物衰竭和移植物功能严重不良相关的移植前后因素","authors":"E. Morozova, T. Rudakova, J. Vlasova, M. Barabanshchikova, Tatiana Gindina, A. Alyanskiy, M. Vladovskaya, I. Moiseev, L. Zubarovskaya, A. Kulagin","doi":"10.18620/ctt-1866-8836-2022-11-1-13-23","DOIUrl":null,"url":null,"abstract":"Summary Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.","PeriodicalId":39111,"journal":{"name":"Cellular Therapy and Transplantation","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia\",\"authors\":\"E. Morozova, T. Rudakova, J. Vlasova, M. Barabanshchikova, Tatiana Gindina, A. Alyanskiy, M. Vladovskaya, I. Moiseev, L. Zubarovskaya, A. Kulagin\",\"doi\":\"10.18620/ctt-1866-8836-2022-11-1-13-23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.\",\"PeriodicalId\":39111,\"journal\":{\"name\":\"Cellular Therapy and Transplantation\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cellular Therapy and Transplantation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18620/ctt-1866-8836-2022-11-1-13-23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Therapy and Transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18620/ctt-1866-8836-2022-11-1-13-23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Pre- and post-transplantation factors associated with primary graft failure and severe poor graft function after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia
Summary Allogeneic stem cell transplantation (allo-HSCT) is used worldwide for long-term management and cure of hematological malignancies, still remaining a valuable option for treatment of chronic myeloid leukemia (CML) in all fit patients who are unable to achieve a durable complete cytogenetic response after treatment with tyrosine kinase inhibitors (TKIs), and in advanced-phase disease. Along with relapse risk, the unfavorable HSCT results may be associated with primary graft failure (PrGF), or poor graft function (PoGF). Hence, the aim of our study was to assess frequency and outcome of PrGF and severe poor graft function (sPGF) after allo-HSCT in CML patients.